دورية أكاديمية
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
| العنوان: | Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? |
|---|---|
| المؤلفون: | Matteo Santoni, Sebastiano Buti, Zin W Myint, Marco Maruzzo, Roberto Iacovelli, Martin Pichler, Jindrich Kopecky, Jakub Kucharz, Mimma Rizzo, Luca Galli, Thomas Büttner, Ugo De Giorgi, Ravindran Kanesvaran, Ondřej Fiala, Enrique Grande, Paolo Andrea Zucali, Ray Manneh Kopp 17, Giuseppe Fornarini, Maria T Bourlon, Sarah Scagliarini, Javier Molina-Cerrillo, Gaetano Aurilio, Marc R Matrana, Renate Pichler, Carlo Cattrini, Tomas Büchler, Francesco Massari, Emmanuel Seront, Fabio Calabrò, Alvaro Pinto, Rossana Berardi, Anca Zgura, Giulia Mammone, Jawaher Ansari, Francesco Atzori, Rita Chiari, Aristotelis Bamias, Orazio Caffo, Giuseppe Procopio, Kaisa Sunela, Maria Bassanelli, Cinzia Ortega, Francesco Grillone, Johannes Landmesser, Michele Milella, Carlo Messina, Zsófia Küronya, Alessandra Mosca, Dipen Bhuva, Daniele Santini, Nuno Vau, Franco Morelli, Lorena Incorvaia, Sara Elena Rebuzzi, Giandomenico Roviello, Andrey Soares, Renato Bisonni, Davide Bimbatti, Ignacio Ortego Zabalza, Alessandro Rizzo, Veronica Mollica, Giulia Sorgentoni, Fernando Sabino M Monteiro, Nicola Battelli, Sergio Bracarda, Camillo Porta |
| المساهمون: | Santoni, Matteo, Buti, Sebastiano, W Myint, Zin, Maruzzo, Marco, Iacovelli, Roberto, Pichler, Martin, Kopecky, Jindrich, Kucharz, Jakub, Rizzo, Mimma, Galli, Luca, Büttner, Thoma, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Andrea Zucali, Paolo, Manneh Kopp 17, Ray, Fornarini, Giuseppe, T Bourlon, Maria, Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, R Matrana, Marc, Pichler, Renate, Cattrini, Carlo, Büchler, Toma, Massari, Francesco, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Bamias, Aristoteli, Caffo, Orazio, Procopio, Giuseppe, Sunela, Kaisa, Bassanelli, Maria, Ortega, Cinzia, Grillone, Francesco, Landmesser, Johanne, Milella, Michele, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Santini, Daniele, Vau, Nuno, Morelli, Franco, Incorvaia, Lorena, Elena Rebuzzi, Sara, Roviello, Giandomenico, Soares, Andrey, Bisonni, Renato, Bimbatti, Davide, Ortego Zabalza, Ignacio, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, M Monteiro, Fernando Sabino, Battelli, Nicola, Bracarda, Sergio, Porta, Camillo |
| سنة النشر: | 2023 |
| المجموعة: | Università degli Studi di Bari Aldo Moro: CINECA IRIS |
| مصطلحات موضوعية: | Keywords: ARON-1 study, Immune-oncology combination, Immunotherapy, Intermediate-risk International Metastatic Renal Cell Carcinoma Database Consortium criteria, NCT05287464, Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium criteria, Renal cell carcinoma, Survival |
| الوصف: | Background: Renal c carcinoma (RCC) is one of the most common urinary cancers worldwide, with a predicted increase in incidence in the coming years. Immunotherapy, as a single agent, in doublets, or in combination with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKIs), has rapidly become a cornerstone of the RCC therapeutic scenario, but no head-to-head comparisons have been made. In this setting, real-world evidence emerges as a cornerstone to guide clinical decisions. Objective: The objective of this retrospective study was to assess the outcome of patients treated with first-line immune combinations or immune oncology (IO)-TKIs for advanced RCC. Design, setting, and participants: Data from 930 patients, 654 intermediate risk and 276 poor risk, were collected retrospectively from 58 centers in 20 countries. Special data such as sarcomatoid differentiation, body mass index, prior nephrectomy, and metastatic localization, in addition to biochemical data such as hemoglobin, platelets, calcium, lactate dehydrogenase, neutrophils, and radiological response by investigator's criteria, were collected. Outcome measurements and statistical analysis: Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. The median follow-up was calculated by the inverse Kaplan-Meier method. Results and limitations: The median follow-up time was 18.7 mo. In the 654 intermediate-risk patients, the median OS and PFS were significantly longer in patients with the intermediate than in those with the poor International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria (38.9 vs 17.3 mo, 95% confidence interval [CI] p < 0.001, and 17.3 vs 11.6 mo, 95% CI p < 0.001, respectively). In the intermediate-risk subgroup, the OS was 55.7 mo (95% CI 31.4-55.7) and 40.2 mo (95% CI 29.6-51.6) in patients treated with IO + TKI and IO + IO combinations, respectively (p = 0.047). PFS was 30.7 mo (95% CI 16.5-55.7) and 13.2 mo (95% CI 29.6-51.6) in ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | info:eu-repo/semantics/altIdentifier/wos/WOS:001171176000001; journal:EUROPEAN UROLOGY ONCOLOGY; https://hdl.handle.net/11586/467980Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85184074251 |
| DOI: | 10.1016/j.euo.2023.07.003 |
| الإتاحة: | https://doi.org/10.1016/j.euo.2023.07.003Test https://hdl.handle.net/11586/467980Test |
| رقم الانضمام: | edsbas.C02CABCA |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.euo.2023.07.003 |
|---|